{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-037322","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.031435+00:00","generated_at":"2026-05-31T09:14:14.726948+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"STRATA Q2 net loss narrows to $0.1M; revenue +2% to $8.4M; gross margin 58.5%","bullets":["Net loss of $0.1M ($0.03 per share) vs $3.1M loss in prior year; operating loss cut to $0.5M from $2.0M.","Revenue $8.4M (+2% YoY); global recurring revenue $5.3M (-2% YoY) due to deferred billings; equipment revenue $3.1M.","Gross margin 58.5% vs 52.3% YoY; operating expenses $5.4M (-14% YoY).","XTRAC domestic base down to 882 from 907 at March; TheraClear X base up to 117 from 104.","Raised $2.1M in July offering; received Japan approval for XTRAC Momentum 1.0; renewed China/Japan distributor pacts."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-037322","json":"https://secwatch.observer/filing/0001140361-24-037322.json","markdown":"https://secwatch.observer/filing/0001140361-24-037322.md","text":"https://secwatch.observer/filing/0001140361-24-037322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124037322/0001140361-24-037322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124037322/ef20034059_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:14:14.726948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}